NCT04706962 - TH1902 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Solid TumorTNBC - Triple-Negative Breast CancerHormone Receptor-positive Breast CancerEpithelial Ovarian CancerEndometrial CancerCutaneous MelanomaThyroid CancerSmall-cell Lung CancerProstate CancerSORT1+ Cancers

Interventions

DRUG

TH1902

Intravenous infusion

Trial Locations (6)

17325

Pennsylvania Cancer Specialists Research Institute, Gettysburg

48201

Karmanos Cancer Institute, Detroit

49546

START Midwest, Grand Rapids

75230

Mary Crowley Cancer Research, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

H2X 0A9

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal